Claudine van der Sande is founder and former CEO of Xinvento, a biotech company launched in 2021. Claudine's motivation for founding Xinvento is her son who is born with congenital hyperinsulinism, a rare disease with high unmet medical need. Claudine, a biomedical scientist by training with positions at Roche, Johnson & Johnson and Sanofi on her resume, scoured the literature and developed a plan to bring a new medicine to families living in fear of CHI. She connected with leading physicians and scientists, patient advocacy groups and many biotech professionals. Two years later, Claudine sold Xinvento to Rhythm Pharmaceuticals and joined the company to lead the CHI program and to complete her mission.